Suven Life Sciences has received Pharmexcil's 'Platinum Patent Award' for securing the most number of product and process patents under overall category fourth year in a row. The Award were presented during the “Awards function for Exports and Patents during India-Asia-Pacific International Pharma Business Meet” organised by Pharmexcil, Department of Commerce and Department of Pharmaceuticals (DoP), Government of India.

Suven secured 96 product patents for their NCE's and nine process patents during 2011-12 from several countries including all the developed countries like USA, Europe, Japan, Australia and Canada, etc. So far Suven secured a total of 541 product patents globally for their NCE's and 36 process patents.

Suven initiated drug discovery research in 2002 and focused on central nervous system (CNS) disorders to discover and develop innovative, cost-effective medicines that address significant unmet medical needs in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson, schizophrenia and also in the area of depression, pain and obesity.

Venkat Jasti, CEO of Suven, said, “We are very pleased by the grant of these patents to Suven globally for our pipeline of molecules in CNS arena that are being developed for the treatment of various unmet medical needs which has an estimated $50 billion market potential globally.”

Suven has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVEN-502 for Alzheimer's disease and schizophrenia.